<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Sixty nine patients were treated with local intra-arterial urokinase (37,500 U/CTA </plain></SENT>
<SENT sid="1" pm="."><plain>hr-1) for recent severe <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> of lower limbs: 27 (40%) ultimately required <z:mpath ids='MPATH_686'>amputation</z:mpath> </plain></SENT>
<SENT sid="2" pm="."><plain>The difference of <z:mpath ids='MPATH_686'>amputation</z:mpath> rate between the groups with and without thrombolysis was not significant (33% v </plain></SENT>
<SENT sid="3" pm="."><plain>42%) </plain></SENT>
<SENT sid="4" pm="."><plain>A biological study in 6 patients showed that local arterial plasminemia occurred in only 1 patient </plain></SENT>
<SENT sid="5" pm="."><plain>Local urokinase does not strongly stimulate "endogenous" thrombolysis and enhances "exogenous" thrombolysis only very inconstantly </plain></SENT>
<SENT sid="6" pm="."><plain>A better adaptation of urokinase dosage or the use of an agent with higher affinity for fibrin might improve the efficiency of local thrombolytic therapy </plain></SENT>
</text></document>